A citation-based method for searching scientific literature

Robert S Kerbel. N Engl J Med 2008
Times Cited: 1587







List of co-cited articles
594 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
18



Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004
10

The biology of VEGF and its receptors.
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter. Nat Med 2003
9



Tumorigenesis and the angiogenic switch.
Gabriele Bergers, Laura E Benjamin. Nat Rev Cancer 2003
8

Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers, Douglas Hanahan. Nat Rev Cancer 2008
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7



Angiogenesis as a therapeutic target.
Napoleone Ferrara, Robert S Kerbel. Nature 2005
6


Basic and therapeutic aspects of angiogenesis.
Michael Potente, Holger Gerhardt, Peter Carmeliet. Cell 2011
6

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Marta Pàez-Ribes, Elizabeth Allen, James Hudock, Takaaki Takeda, Hiroaki Okuyama, Francesc Viñals, Masahiro Inoue, Gabriele Bergers, Douglas Hanahan, Oriol Casanovas. Cancer Cell 2009
6

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Christopher G Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Ricky T Tong, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Sergey V Kozin,[...]. Nat Med 2004
5

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
5

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, Lee B Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P Michael,[...]. Sci Transl Med 2017
288
5

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Yuhui Huang, Jianping Yuan, Elda Righi, Walid S Kamoun, Marek Ancukiewicz, Jean Nezivar, Michael Santosuosso, John D Martin, Margaret R Martin, Fabrizio Vianello,[...]. Proc Natl Acad Sci U S A 2012
501
5

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
5

VEGF receptor signalling - in control of vascular function.
Anna-Karin Olsson, Anna Dimberg, Johan Kreuger, Lena Claesson-Welsh. Nat Rev Mol Cell Biol 2006
5

Vessel co-option in cancer.
Elizabeth A Kuczynski, Peter B Vermeulen, Francesco Pezzella, Robert S Kerbel, Andrew R Reynolds. Nat Rev Clin Oncol 2019
110
5

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
959
5


VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara. Cell 2019
395
5


Angiogenesis in cancer and other diseases.
P Carmeliet, R K Jain. Nature 2000
5

Targeting HIF-1 for cancer therapy.
Gregg L Semenza. Nat Rev Cancer 2003
5

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, Adil Daud, F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D Wolchok, Peter Hersey, Richard W Joseph, Jeffrey S Weber,[...]. N Engl J Med 2013
4

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, Peter J O'Dwyer, Edith P Mitchell, Steven R Alberts, Michael A Schwartz, Al B Benson. J Clin Oncol 2007
4

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
4

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
788
4

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
4

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
4

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004
4

VEGF targets the tumour cell.
Hira Lal Goel, Arthur M Mercurio. Nat Rev Cancer 2013
660
4

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Gregory T Motz, Stephen P Santoro, Li-Ping Wang, Tom Garrabrant, Ricardo R Lastra, Ian S Hagemann, Priti Lal, Michael D Feldman, Fabian Benencia, George Coukos. Nat Med 2014
432
4

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
4

On the origin of cancer cells.
O WARBURG. Science 1956
4

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
4

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Thibault Voron, Orianne Colussi, Elie Marcheteau, Simon Pernot, Mevyn Nizard, Anne-Laure Pointet, Sabrina Latreche, Sonia Bergaya, Nadine Benhamouda, Corinne Tanchot,[...]. J Exp Med 2015
448
4

Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Yuhui Huang, Shom Goel, Dan G Duda, Dai Fukumura, Rakesh K Jain. Cancer Res 2013
335
4

Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Ju Yang, Jing Yan, Baorui Liu. Front Immunol 2018
177
4

Targeting the tumour vasculature: insights from physiological angiogenesis.
Alicia S Chung, John Lee, Napoleone Ferrara. Nat Rev Cancer 2010
479
4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
4

Ten years of anti-vascular endothelial growth factor therapy.
Napoleone Ferrara, Anthony P Adamis. Nat Rev Drug Discov 2016
411
4

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
John M L Ebos, Robert S Kerbel. Nat Rev Clin Oncol 2011
488
4

5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2.
Umesh Bhanushali, Saranya Rajendran, Keerthana Sarma, Pushkar Kulkarni, Kiranam Chatti, Suvro Chatterjee, C S Ramaa. Bioorg Chem 2016
20
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.